Ningxia Zhongke Biotechnology Co., Ltd.
600165.SS · SHH
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | CN¥1,664 | CN¥2,341 | CN¥4,630 | CN¥9,198 |
| - Cash | CN¥9 | CN¥24 | CN¥89 | CN¥111 |
| + Debt | CN¥228 | CN¥559 | CN¥985 | CN¥917 |
| Enterprise Value | CN¥1,883 | CN¥2,876 | CN¥5,525 | CN¥10,004 |
| Revenue | CN¥345 | CN¥286 | CN¥681 | CN¥192 |
| % Growth | 20.9% | -58.1% | 254% | – |
| Gross Profit | -CN¥67 | -CN¥135 | CN¥76 | CN¥24 |
| % Margin | -19.5% | -47.1% | 11.1% | 12.4% |
| EBITDA | -CN¥306 | -CN¥235 | CN¥49 | -CN¥135 |
| % Margin | -88.7% | -82.3% | 7.2% | -69.9% |
| Net Income | -CN¥539 | -CN¥466 | -CN¥170 | -CN¥30 |
| % Margin | -156.1% | -162.9% | -25% | -15.6% |
| EPS Diluted | -0.79 | -0.68 | -0.25 | -0.044 |
| % Growth | -16.2% | -172% | -472.1% | – |
| Operating Cash Flow | -CN¥85 | CN¥23 | CN¥53 | -CN¥8 |
| Capital Expenditures | -CN¥6 | -CN¥58 | -CN¥59 | -CN¥251 |
| Free Cash Flow | -CN¥91 | -CN¥35 | -CN¥6 | -CN¥258 |